Curium to acquire Lantheus to become a radiopharmaceutical company of scale

Leslie Cui

— 1 min read
Curium to acquire Lantheus to become a radiopharmaceutical company of scale
Photo by National Cancer Institute / Unsplash

Curium has entered a definitive agreement to acquire Lantheus in a deal worth up to $8 billion. Curium develops, manufactures, and supplies of radiopharmaceuticals used in diagnosing and treating cancer. The company holds patents on the compositions, formulations, purification processes, and systems and methods of use of radioactive isotope of copper (Cu-64), Cu-64 dotatate injection (Detectnet™), synthetic radioactive isotope of germanium (Ge-68), Technetium Tc-99m (metastable radioactive isotope of technetium and the most widely used medical tracer in the world) generator (Ultra-Technekow™ V4), and several other device used to generate radioisotopes. Lantheus is a leading radiopharmaceutical company specialized in making diagnostic imaging agents to “Find, Fight and Follow” disease. Its flagship products include Pylarify, a PET imaging agent to detect prostate-specific membrane antigen-positive lesions in prostate cancer, and Definity, an ultrasound contrast agent to enhance the echocardiogram image quality.

[This post is for educational purposes only. It reflects my own analysis of publicly available information, does not constitute legal advice, and does not create an agent-client relationship. Views expressed are my own, not those of any employer or client.]

Read more

GSK acquires Chimagen’s trispecific T-cell engager: analysis of multispecific antibody space and Chimagen patent

GSK acquires Chimagen’s trispecific T-cell engager: analysis of multispecific antibody space and Chimagen patent

Multispecific antibodies have emerged as a promising class of cancer immunotherapeutics to target multiple epitopes for improved tumor selectivity and clinical efficacy. Bispecific and trispecific antibodies are engineered to contain two and three binding sites, respectively, allowing them to engage multiple cell types to trigger a more precise and thorough

By Leslie Cui
10x Genomics and Parse single-cell sequencing patents split fates, Rasonque (daraxonrasib) approval, and autogene cevumeran phase 2 study termination

10x Genomics and Parse single-cell sequencing patents split fates, Rasonque (daraxonrasib) approval, and autogene cevumeran phase 2 study termination

IP litigation between 10x Genomics and Parse Biosciences in single-cell sequencing turned on Aug 28, when a Delaware jury found that Parse’s Evercode Whole Transcriptome products willfully infringed three Roche-originating patents exclusively licensed to Scale Biosciences ruled, which 10x Genomics acquired in 2025. The verdict came just nine days

By Leslie Cui